ALTAO
Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquart… Read more
Market Cap & Net Worth: ALTAO (ALTAO)
ALTAO (PA:ALTAO) has a market capitalization of $4.93 Million (€4.80 Million) as of March 19, 2026. Listed on the PA stock exchange, this France-based company holds position #34397 globally and #411 in its home market, demonstrating a -3.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ALTAO's stock price €0.01 by its total outstanding shares 828118245 (828.12 Million).
ALTAO Market Cap History: 2025 to 2026
ALTAO's market capitalization history from 2025 to 2026. Data shows growth from $6.12 Million to $4.93 Million (0.00% CAGR).
ALTAO Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ALTAO's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ALTAO by Market Capitalization
Companies near ALTAO in the global market cap rankings as of March 19, 2026.
Key companies related to ALTAO by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ALTAO Historical Marketcap From 2025 to 2026
Between 2025 and today, ALTAO's market cap moved from $6.12 Million to $ 4.93 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.93 Million | -19.44% |
| 2025 | €6.12 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of ALTAO was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.93 Million USD |
| MoneyControl | $4.93 Million USD |
| MarketWatch | $4.93 Million USD |
| marketcap.company | $4.93 Million USD |
| Reuters | $4.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.